Lucid Diagnostics Announces Closing of Public Offering of Common Stock

▤ Summary

Lucid Diagnostics closed its previously announced public offering of common stock and sold 28,750,000 shares, including the full exercise of the underwriters' option. The company expects to receive about $26.9 million in net proceeds after fees and expenses. Lucid plans to use the money for working capital and general corporate purposes. Lucid is a commercial-stage cancer prevention diagnostics company focused on early detection of esophageal precancer in at-risk patients.

$ Funding

▦ Linked Companies